Novo Nordisk close to releasing phase III hemophilia data
The pharmaceutical group is ”a few weeks” away from publishing results, says the EVP of Development.
af marketwire
Novo Nordisk is about to release data from a phase III study of hemophilia treatment Mim8, which is in-licensed from Genmab, according to Danish media Børsen.
”We’re only a few weeks away from a results reading with Mim8, so it will be exciting,” Martin Holst Lange, EVP, Development at Novo Nordisk, told analysts and investors at an investor meeting in connection with the recent release of the pharmaceutical group’s quarterly report.
According to estimates from the major American bank Citi, the drug could eventually reach annual sales of DKK 13.2bn (USD 1.9bn), writes Børsen.
The drug can thus help restore growth in Novo’s rare disease business, which saw revenue decline by 15% last year.
